Evaluating Intermittent Fasting In Individuals At High Risk ForPancreatic Cancer Undergoing Screening
Evaluating Intermittent Fasting In Individuals At High Risk ForPancreatic Cancer Undergoing Screening
To learn whether an eating pattern called intermittent fasting (IF) is tolerable and feasible for individuals at high risk of pancreatic cancer and whether IF is associated with changes in biological markers, including metabolic, inflammatory, microbiome, and imaging-related markers.
Primary Objectives
• To assess the tolerability and feasibility of Intermittent fasting (IF) in participants at high risk for pancreatic cancer.
Secondary Objectives
Inclusion Criteria
Participants ≥ 18 years old. Participants under 18 are excluded due to their potential inability to understand and consent independently to the methods required for the study drug use and its potential risks and benefits.
Participants evaluated and classified as high risk for pancreatic cancer through a High-Risk Pancreatic Cancer Clinic or High-Risk Pancreatic Cyst Clinic, based on established clinical assessment and risk stratification.
High-risk status may include one or more of the following:
Eligibility and surveillance risk assessment must be consistent with NCCN (National Comprehensive Cancer Network) Guidelines for Pancreatic Cancer Screening in High- Risk Individuals.
Participants are able to understand and are willing to sign a written informed consent document.
Both English-speaking and non-English-speaking participants are eligible for participation
Participants are willing to make a change in eating time patterns.
Participants are willing to provide App-tracked fasting time data over the course of the study.
Exclusion Criteria
fmcallister@mdanderson.org713-745-0914